{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:12:08Z","timestamp":1772791928986,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T00:00:00Z","timestamp":1306281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This study examined the outcome of 248 Waldenstrom macroglobulinaemia (WM) rituximab\u2010na\u00efve patients who responded to a rituximab\u2010containing regimen. Eighty\u2010six patients (35%) subsequently received maintenance rituximab (M\u2010Rituximab). No differences in baseline characteristics, and post\u2010induction categorical responses between cohorts were observed. The median rituximab infusions during induction was 6 for both cohorts; and 8 over a 2\u2010year period for patients receiving M\u2010Rituximab. Categorical responses improved in 16\/162 (10%) of observed, and 36\/86 (41\u00b78%) of M\u2010Rituximab patients respectively, following induction therapy (<jats:italic>P<\/jats:italic>\u2003&lt; 0\u00b70001). Both progression\u2010free (56\u00b73 vs. 28\u00b76\u2003months; <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b70001) and overall survival (Not reached <jats:italic>versus<\/jats:italic> 116\u2003months; <jats:italic>P<\/jats:italic>\u2003=\u20030\u00b70095) were longer in patients who received M\u2010Rituximab. Improved progression\u2010free survival was evident despite previous treatment status, induction with rituximab alone or in combination therapy (<jats:italic>P<\/jats:italic>\u2003\u2264\u20030\u00b70001). Best serum IgM response was lower (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b70001), and haematocrit higher (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7001) for patients receiving M\u2010Rituximab. Among patients receiving M\u2010Rituximab, an increased number of infectious events were observed, but were mainly \u2264grade 2 (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7008). The findings of this observational study suggest improved clinical outcomes following M\u2010Rituximab in WM patients who respond to induction with a rituximab\u2010containing regimen. Prospective studies aimed at clarifying the role of M\u2010Rituximab therapy in WM patients are needed to confirm these findings.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08750.x","type":"journal-article","created":{"date-parts":[[2011,5,25]],"date-time":"2011-05-25T16:48:10Z","timestamp":1306342090000},"page":"357-362","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Maintenance Rituximab is associated with improved clinical outcome in rituximab na\u00efve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab\u2010containing regimen"],"prefix":"10.1111","volume":"154","author":[{"given":"Steven P.","family":"Treon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Hanzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leukothea","family":"Ioakimidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary R.","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Sheehy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Turnbull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,5,25]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.039"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7865"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-016725"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001714043"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3411"},{"key":"e_1_2_5_8_1","article-title":"Rituximab as first\u2010line and maintenance therapy for patients (Pts) with indolent non\u2010hodgkin\u2019s lymphoma (NHL)","volume":"20","author":"Hainsworth J.D.","year":"2001","journal-title":"Proceedings American Society Clinical Oncology"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.027"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.191"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.010348"},{"key":"e_1_2_5_13_1","article-title":"Preliminary Pharmacokinetic (PK) Analysis of Eastern Cooperative Oncology Group Protocol E4402: rituximab Extended Schedule or Re\u2010Treatment Trial (RESORT)","volume":"110","author":"Kahl B.S.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.013"},{"key":"e_1_2_5_15_1","article-title":"Chimeric Anti\u2010CD20 Monoclonal Antibody (Rituximab; Mabthera\u00ae) in Remission Induction and Maintenance Treatment of Relapsed\/Resistant Follicular Non\u2010Hodgkin\u2019s Lymphoma: a Phase III Randomized Intergroup Clinical Trial","volume":"104","author":"van Oers M.H.J.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2003.50082"},{"key":"e_1_2_5_18_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.8534","article-title":"First results of long term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35\/03","volume":"27","author":"Taverna C.J.","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-174359"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200105000-00012"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi022"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0833"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-177329"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4677"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08726.x"},{"key":"e_1_2_5_26_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.8606","article-title":"Safety in patients receiving maintenance rituximab for follicular lymphoma: results from the phase IIIb MAXIMA trial","volume":"26","author":"Wenger M.K.","year":"2008","journal-title":"Journal of Clinical Oncology"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08750.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08750.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:16:41Z","timestamp":1697422601000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08750.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,25]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08750.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08750.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,25]]},"assertion":[{"value":"2011-05-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}